135 related articles for article (PubMed ID: 32386876)
1. Amyloid Evolvability and Cancer.
Takamatsu Y; Ho G; Hashimoto M
Trends Cancer; 2020 Aug; 6(8):624-627. PubMed ID: 32386876
[TBL] [Abstract][Full Text] [Related]
2. Amyloidogenicity of p53: a hidden link between protein misfolding and cancer.
Gong H; Yang X; Zhao Y; Petersen RB; Liu X; Liu Y; Huang K
Curr Protein Pept Sci; 2015; 16(2):135-46. PubMed ID: 25692950
[TBL] [Abstract][Full Text] [Related]
3. Understanding Creutzfeldt-Jackob disease from a viewpoint of amyloidogenic evolvability.
Hashimoto M; Ho G; Takamatsu Y; Wada R; Sugama S; Waragai M; Masliah E; Takenouchi T
Prion; 2020 Dec; 14(1):1-8. PubMed ID: 32375593
[TBL] [Abstract][Full Text] [Related]
4. Antitumor mechanisms when pRb and p53 are genetically inactivated.
Zhu L; Lu Z; Zhao H
Oncogene; 2015 Aug; 34(35):4547-57. PubMed ID: 25486431
[TBL] [Abstract][Full Text] [Related]
5. Long non-coding RNA AK058003, as a precursor of miR-15a, interacts with HuR to inhibit the expression of γ-synuclein in hepatocellular carcinoma cells.
He X; Zheng Y; Zhang Y; Gan Y; Zhou Y; Liang H; Wu D; Ge W; Deng J; Xu X
Oncotarget; 2017 Feb; 8(6):9451-9465. PubMed ID: 28035067
[TBL] [Abstract][Full Text] [Related]
6. Adiponectin paradox as a therapeutic target of the cancer evolvability in aging.
Takamatsu Y; Ho G; Wada R; Inoue S; Hashimoto M
Neoplasia; 2021 Jan; 23(1):112-117. PubMed ID: 33310207
[TBL] [Abstract][Full Text] [Related]
7. Effects of phosphatidylcholine membrane fluidity on the conformation and aggregation of N-terminally acetylated α-synuclein.
O'Leary EI; Jiang Z; Strub MP; Lee JC
J Biol Chem; 2018 Jul; 293(28):11195-11205. PubMed ID: 29853639
[TBL] [Abstract][Full Text] [Related]
8. Synuclein-gamma is closely involved in perineural invasion and distant metastasis in mouse models and is a novel prognostic factor in pancreatic cancer.
Hibi T; Mori T; Fukuma M; Yamazaki K; Hashiguchi A; Yamada T; Tanabe M; Aiura K; Kawakami T; Ogiwara A; Kosuge T; Kitajima M; Kitagawa Y; Sakamoto M
Clin Cancer Res; 2009 Apr; 15(8):2864-71. PubMed ID: 19351749
[TBL] [Abstract][Full Text] [Related]
9. Evolvability of Amyloidogenic Proteins in Human Brain.
Hashimoto M; Ho G; Sugama S; Takamatsu Y; Shimizu Y; Takenouchi T; Waragai M; Masliah E
J Alzheimers Dis; 2018; 62(1):73-83. PubMed ID: 29439348
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic gain of function due to p53 amyloids occurs through aberrant alteration of cell cycle and proliferation.
Navalkar A; Paul A; Sakunthala A; Pandey S; Dey AK; Saha S; Sahoo S; Jolly MK; Maiti TK; Maji SK
J Cell Sci; 2022 Aug; 135(15):. PubMed ID: 35796018
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of synuclein-gamma expression increases the sensitivity of breast cancer cells to paclitaxel treatment.
Zhou Y; Inaba S; Liu J
Int J Oncol; 2006 Jul; 29(1):289-95. PubMed ID: 16773211
[TBL] [Abstract][Full Text] [Related]
12. Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor.
Silva JL; Rangel LP; Costa DC; Cordeiro Y; De Moura Gallo CV
Biosci Rep; 2013 Jul; 33(4):. PubMed ID: 24003888
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of p53: effect on prognosis, tumor progression and chemotherapy response.
Peller S
Semin Cancer Biol; 1998; 8(5):379-87. PubMed ID: 10101803
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of SNCG suppresses the proliferation of lung cancer cells induced by high glucose.
Fei J; Xiao C; Yang M; Zhou X; Gong P
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33313952
[TBL] [Abstract][Full Text] [Related]
15. Mesoscopic protein-rich clusters host the nucleation of mutant p53 amyloid fibrils.
Yang DS; Saeedi A; Davtyan A; Fathi M; Sherman MB; Safari MS; Klindziuk A; Barton MC; Varadarajan N; Kolomeisky AB; Vekilov PG
Proc Natl Acad Sci U S A; 2021 Mar; 118(10):. PubMed ID: 33653952
[TBL] [Abstract][Full Text] [Related]
16. p53 amyloid formation leading to its loss of function: implications in cancer pathogenesis.
Ghosh S; Salot S; Sengupta S; Navalkar A; Ghosh D; Jacob R; Das S; Kumar R; Jha NN; Sahay S; Mehra S; Mohite GM; Ghosh SK; Kombrabail M; Krishnamoorthy G; Chaudhari P; Maji SK
Cell Death Differ; 2017 Oct; 24(10):1784-1798. PubMed ID: 28644435
[TBL] [Abstract][Full Text] [Related]
17. Clinical study of the relationship between γ-synuclein and the response of neoadjuvant chemotherapy in breast cancer.
Wan F; Dong L; Zhang F; Wang Y; Chen F; Ni S; Chen Y; Long J
J Int Med Res; 2013 Jun; 41(3):743-53. PubMed ID: 23696593
[TBL] [Abstract][Full Text] [Related]
18. Dimebon reduces the levels of aggregated amyloidogenic protein forms in detergent-insoluble fractions in vivo.
Ustyugov AA; Shelkovnikova TA; Kokhan VS; Khritankova IV; Peters O; Buchman VL; Bachurin SO; Ninkina NN
Bull Exp Biol Med; 2012 Apr; 152(6):731-3. PubMed ID: 22803176
[TBL] [Abstract][Full Text] [Related]
19. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
Stiewe T; Haran TE
Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
[TBL] [Abstract][Full Text] [Related]
20. Effects of γ-synuclein on the tumorigenicity and metastasis of colon cancer SW1116 cells in vitro and in vivo.
Ye Q; Huang F; Wang XY; Xu YM; Gong FS; Huang LJ; Yang CK; Zheng QH; Ying MG
Oncol Rep; 2013 Nov; 30(5):2161-70. PubMed ID: 23970348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
